182 related articles for article (PubMed ID: 35166967)
1. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
3. Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study.
Pouzin C; Tod M; Chadjaa M; Fagniez N; Nguyen L
CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):384-394. PubMed ID: 35191618
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
[TBL] [Abstract][Full Text] [Related]
5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
6. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
7. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
9. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
[TBL] [Abstract][Full Text] [Related]
10. Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates.
Goldmacher VS; Amphlett G; Wang L; Lazar AC
Mol Pharm; 2015 Jun; 12(6):1738-44. PubMed ID: 25635630
[TBL] [Abstract][Full Text] [Related]
11. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lefebvre AM; Adam J; Nicolazzi C; Larois C; Attenot F; Falda-Buscaiot F; Dib C; Masson N; Ternès N; Bauchet AL; Demers B; Chadjaa M; Sidhu S; Combeau C; Soria JC; Scoazec JY; Naimi S; Angevin E; Chiron M; Henry C
Lung Cancer; 2023 Oct; 184():107356. PubMed ID: 37660479
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
13. Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach.
Pouzin C; Teutonico D; Fagniez N; Ziti-Ljajic S; Perreard-Dumaine A; Pardon M; Klieber S; Nguyen L
Clin Pharmacol Ther; 2024 Feb; 115(2):278-287. PubMed ID: 37964462
[TBL] [Abstract][Full Text] [Related]
14. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
15. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
[TBL] [Abstract][Full Text] [Related]
16. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.
Cilliers C; Guo H; Liao J; Christodolu N; Thurber GM
AAPS J; 2016 Sep; 18(5):1117-1130. PubMed ID: 27287046
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
[TBL] [Abstract][Full Text] [Related]
18. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
19. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
Tabernero J; Bedard PL; Bang YJ; Vieito M; Ryu MH; Fagniez N; Chadjaa M; Soufflet C; Masson N; Gazzah A
Cancer Res Commun; 2023 Aug; 3(8):1662-1671. PubMed ID: 37645622
[TBL] [Abstract][Full Text] [Related]
20. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
